We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
French biopharmaceutical company Antabio has secured a non-dilutive funding to accelerate the development of a new small molecule drug to treat chronic Pseudomonas infections in cystic fibrosis patients.